

WT1 235-243 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0490

DESCRIPTION	
Product Name	WT1 235-243 Circular RNA for Cancer Vaccine Research
Gene Name	WT1 235-243
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	WT1 235-243 Peptide Vaccine
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	WT1 235-243
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Lonizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	WT1 235-243 Peptide Vaccine

leukemia and in a variety of solid cancers. (NCIT_C104734).

Background

Description: A synthetic peptide vaccine consisting of a HLA-A24-restricted human Wilms' Tumor protein-1 (WT1) peptide comprised of amino acids 235 through 243, a MHC class I-restricted peptide, with potential immunomodulating and antitumor activities. Vaccination with WT1 235-243 peptide may induce a WT1-specific cytotoxic T-lymphocyte (CTL) response against WT1 expressing cells, resulting in cell lysis and inhibition of cancer cell proliferation. WT1, a zinc finger DNA-binding protein, is overexpressed in most types of